Barclays’s BioTelemetry, Inc. BEAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-224,418
| Closed | -$16.2M | – | 5422 |
|
|
2020
Q4 | $16.2M | Buy |
224,418
+168,167
| +299% | +$8.8M | 0.01% | 921 |
|
|
2020
Q3 | $2.56M | Buy |
56,251
+25,508
| +83% | +$1.07M | ﹤0.01% | 1890 |
|
|
2020
Q2 | $1.39M | Sell |
30,743
-42,280
| -58% | -$1.89M | ﹤0.01% | 2448 |
|
|
2020
Q1 | $2.81M | Sell |
73,023
-22,176
| -23% | -$1.02M | ﹤0.01% | 1968 |
|
|
2019
Q4 | $4.41M | Buy |
95,199
+56,929
| +149% | +$2.47M | ﹤0.01% | 2142 |
|
|
2019
Q3 | $1.56M | Sell |
38,270
-32,541
| -46% | -$1.4M | ﹤0.01% | 3173 |
|
|
2019
Q2 | $3.41M | Buy |
70,811
+13,219
| +23% | +$695K | ﹤0.01% | 2284 |
|
|
2019
Q1 | $3.61M | Buy |
57,592
+28,761
| +100% | +$1.98M | ﹤0.01% | 1957 |
|
|
2018
Q4 | $1.72M | Sell |
28,831
-64,567
| -69% | -$3.88M | ﹤0.01% | 2556 |
|
|
2018
Q3 | $6.02M | Buy |
93,398
+65,544
| +235% | +$3.66M | ﹤0.01% | 1619 |
|
|
2018
Q2 | $1.25M | Buy |
27,854
+13,191
| +90% | +$526K | ﹤0.01% | 3037 |
|
|
2018
Q1 | $455K | Buy |
14,663
+7,116
| +94% | +$234K | ﹤0.01% | 4070 |
|
|
2017
Q4 | $226K | Sell |
7,547
-4,131
| -35% | -$120K | ﹤0.01% | 4580 |
|
|
2017
Q3 | $385K | Sell |
11,678
-8,845
| -43% | -$306K | ﹤0.01% | 3866 |
|
|
2017
Q2 | $687K | Sell |
20,523
-41,251
| -67% | -$1.23M | ﹤0.01% | 3215 |
|
|
2017
Q1 | $1.79M | Buy |
61,774
+52,842
| +592% | +$1.31M | ﹤0.01% | 2202 |
|
|
2016
Q4 | $199K | Buy |
8,932
+4,497
| +101% | +$87.9K | ﹤0.01% | 4219 |
|
|
2016
Q3 | $82K | Buy |
4,435
+689
| +18% | +$13K | ﹤0.01% | 4649 |
|
|
2016
Q2 | $61K | Buy |
3,746
+3,741
| +74,820% | +$55K | ﹤0.01% | 4732 |
|
|
2016
Q1 | $0 | Buy |
+5
| New | +$56 | ﹤0.01% | 6849 |
|
|
2015
Q4 | – | Sell |
-141
| Closed | -$2K | – | 7252 |
|
|
2015
Q3 | $2K | Sell |
141
-3,619
| -96% | -$46.1K | ﹤0.01% | 6468 |
|
|
2015
Q2 | $34K | Buy |
3,760
+2,925
| +350% | +$27.1K | ﹤0.01% | 5391 |
|
|
2015
Q1 | $7K | Sell |
835
-11,411
| -93% | -$115K | ﹤0.01% | 6495 |
|
|
2014
Q4 | $122K | Buy |
12,246
+9,832
| +407% | +$84.3K | ﹤0.01% | 5031 |
|
|
2014
Q3 | $15K | Buy |
2,414
+290
| +14% | +$2.03K | ﹤0.01% | 6684 |
|
|
2014
Q2 | $15K | Buy |
2,124
+579
| +37% | +$4.61K | ﹤0.01% | 6651 |
|
|
2014
Q1 | $15K | Sell |
1,545
-138
| -8% | -$1.27K | ﹤0.01% | 6754 |
|
|
2013
Q4 | $12K | Sell |
1,683
-662
| -28% | -$6.18K | ﹤0.01% | 6962 |
|
|
2013
Q3 | $21K | Sell |
2,345
-100
| -4% | -$787 | ﹤0.01% | 6519 |
|
|
2013
Q2 | $14K | Buy |
+2,445
| New | +$8.23K | ﹤0.01% | 7013 |
|
Other funds holding BEAT
Barclays's BEAT Position: Q1 2021 in Review
Barclays sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 224,418 shares — an estimated $16.2M sold.
Barclays first reported a position in BEAT in Q2 2013 and held it in 30 quarters. The position peaked at $16.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.
- Barclays reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
- Barclays sold 224,418 BioTelemetry, Inc. shares in Q1 2021, an estimated $16.2M.
- Barclays first reported a position in BioTelemetry, Inc. in Q2 2013 and held it in 30 quarters.
- Barclays's BioTelemetry, Inc. position peaked at $16.2M in Q4 2020.
- 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.
Based on Barclays's 13F filing for Q1 2021, filed 13 May 2021.